KNOMATIC
Live / Applied — Final refusal mailed (as of 10 Feb 2026)
What this means for you
Not registered yet, but its 27 Aug 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98720113
- Mark type
- Stylized text
- Filed
- 27 Aug 2024
- Attorney of record
- Gregory B. Coy
Goods and services
- Class 005 — Pharmaceuticals: chemical and biochemical preparations and substances for medical purposes for treatment and diagnosis of cancer, autoimmune disease, and other diseases that involve the functionality of highly dynamic proteins; immunotherapy products, namely, pharmaceutical preparations for the treatment of cancer, autoimmune diseases, and immunological disorders
- Class 042 — Scientific and technological services: drug discovery services; pharmaceutical research services; pharmaceutical products development; pharmaceutical research and development; pharmaceutical drug development services; consulting services in the field of pharmaceutical research and development; technical consulting in the field of pharmaceutical studies; technical research in the field of pharmaceutical studies; research and development services of new pharmaceutical products; research and development in the pharmaceutical and biotechnology fields; providing medical research information in the field of pharmaceuticals; providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research in the field of bioinformatics; biological and bio-technology analysis services; DNA sequencing technology research; research in the field of DNA mutation; DNA analysis services for scientific research purposes; providing genetic science information; scientific research consulting in the field of pharmaceuticals and drug discovery; medical and scientific research in the field of proteomics; scientific research for medical purposes in the field of proteomics; drug discovery services that utilize structural analysis, hit finding techniques and computational analysis and targets diseases related to highly dynamic proteins; drug discovery services, namely, drug design; drug discovery services, namely, analysis of structure activity relationships; drug discovery services, namely, medical research and development; drug discovery services, namely, DNA encoded library (DEL) screening; drug discovery services, namely, genetic sequencing services; using artificial intelligence (AI) for drug discovery, pharmaceutical research and development, and medical research and development in the fields of pharmaceuticals and genetics; using machine learning for drug discovery, pharmaceutical research and development, and medical research and development in the fields of pharmaceuticals and genetics; drug discovery services targeting diseases related to highly dynamic proteins by utilizing structural analysis, hit finding techniques and computational analysis; drug discovery services for use in developing and prioritizing lead compounds for drug development; drug discovery services in the fields of biochemistry, biophysics, structural biology and chemistry; drug discovery services in the nature of a knowledge based drug discovery platform; drug discovery services in the nature of data analysis software for use in drug discovery; drug discovery services in the nature of drug discovery software utilizing hit finding techniques
Owner
- Moma Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 10 Feb 2026 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 10 Feb 2026 — FINAL REFUSAL E-MAILED
- 10 Feb 2026 — FINAL REFUSAL WRITTEN
- 12 Jan 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 12 Jan 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 12 Jan 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 03 Oct 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 03 Oct 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 14 Jul 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 14 Jul 2025 — NON-FINAL ACTION E-MAILED
- 14 Jul 2025 — NON-FINAL ACTION WRITTEN
- 10 Jun 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 10 Jun 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 10 Jun 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 11 Mar 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED